Messinger Michael purchased $2K of ICU
Messinger Michael (Chief Financial Officer) purchased 2,500 shares of SeaStar Medical Holding Corp (ICU) at $0.85 on 2026-11-16.
SeaStar Medical Holding Corp
SeaStar Medical is a commercial-stage healthcare company developing and commercializing treatments for critically ill patients facing organ failure and other serious inflammatory diseases. Its Selective Cytopheretic Device (SCD) is an extracorporeal membrane device designed to modulate activated immune cells and is used with continuous renal replacement therapy systems. SeaStar Medical’s first commercial product, QUELIMMUNE, is an SCD therapy for critically ill pediatric patients with acute kidney injury due to sepsis or a septic condition. It has FDA approval under a Humanitarian Device Exemption and is sold to qualified healthcare facilities. The company also conducts clinical studies of SCD therapy in adults, including a pivotal trial for acute kidney injury and a feasibility study in cardiorenal syndrome. SeaStar Medical is headquartered in Denver, Colorado.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Messinger Michael (Chief Financial Officer) purchased 2,500 shares of SeaStar Medical Holding Corp (ICU) at $0.85 on 2026-11-16.
Chung Kevin (Chief Medical Officer) purchased 7,800 shares of SeaStar Medical Holding Corp (ICU) at $0.84 on 2026-11-16.
SeaStar Medical Holding Corp (ICU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates Continued adoption of the QUELIMMUNE ® therapy yielded 247% increase in net revenue compared to the third quarter of 2025 Achieved nearly 75% enrollment in the NEUTRALIZE-AKI p
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning ICU (SeaStar Medical Holding Corp). Coverage has skewed bearish: 0 bullish, 1 neutral, and 3 bearish.
Recent ICU coverage spans earnings, financial news and insider activity.
In the last 30 days, ICU insiders filed 2 SEC Form 4 transactions — 2 purchases ($9K) and no sales. The most active reporter was Chung Kevin, Chief Medical Officer, with 1 filing.
Small insider open-market purchase is mildly supportive sentiment but unlikely to drive near-term repricing.
Insider open-market buying is modest and may be read as mild confidence, but it is unlikely to drive a large repricing by itself.
Earnings miss with large loss offsets by strong trial progress and regulatory milestone.
Positive earnings surprise and guidance raise expectations for near‑term upside.
The strong revenue growth and advanced trial enrollment suggest improving commercial prospects and potential regulatory approval.
AlphAI scores every news story that mentions ICU with an AI model for sentiment and relevance, and aggregates insider trades from SeaStar Medical Holding Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Messinger Michael (Chief Financial Officer) purchased 2,500 shares of SeaStar Medical Holding Corp (ICU) at $0.85 on 2026-11-16.
Chung Kevin (Chief Medical Officer) purchased 7,800 shares of SeaStar Medical Holding Corp (ICU) at $0.84 on 2026-11-16.
SeaStar Medical Holding Corp (ICU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates Continued adoption of the QUELIMMUNE ® therapy yielded 247% increase in net revenue compared to the third quarter of 2025 Achieved nearly 75% enrollment in the NEUTRALIZE-AKI p
SeaStar Medical (ICU) reported Q3 2026 revenue growth of 247% YoY, driven by QUELIMMUNE sales. Nine-month sales suggest FY2026 guidance of $2 million is achievable. NEUTRALIZE-AKI trial enrollment delayed to mid-2027, with adult-AKI PMA work ongoing.
SeaStar Medical (ICU) reported Q3 revenue of $635K, up 247% YoY, with gross margins above 90%. Net loss widened to $4.529M. The NEUTRALIZE-AKI trial enrolled 251 of 339 patients, and the first PMA module was submitted to the FDA.
SeaStar Medical (ICU) reported Q3 2026 revenue of $0.6M, up 247% YoY. Net loss increased to $4.5M from $3.5M, with $4.0M cash on hand. The company is in early commercial stage, growing QUELIMMUNE sales and advancing a pivotal trial.
ICU Medical reported Q3 2026 results with Infusion Systems and Consumables segments growing, while Vital Care declined due to logistics issues. Gross margin rose to 42%, with management targeting 43%. Future growth is expected from product launches and innovation. The stock is trading at $162, down from $167.65 pre-earnings.
Keybanc maintained its Overweight rating on ICU Medical and increased its price target to $189 from $187, suggesting a 12.7% upside from the Nov 5 close of $167.65, according to the firm.
Piper Sandler kept ICU Medical at Overweight, raising its price target to $200 from $195, suggesting a 19.3% upside from the Nov 5 close of $167.65.
SeaStar Medical (ICU) will report Q3 2026 results on Nov. 11, 2026, with a live call requiring preregistration. The company focuses on treatments for organ failure, with one FDA-approved product and ongoing clinical trials. ICU's SCD therapy has Breakthrough Device Designation for seven indications.